Lyme vaccines: efficacy shown, Europe filed, and now the demand question.
Pfizer and Valneva's LB6V (PF-07307405) has delivered 73.2% efficacy in a 9,437-participant Phase 3, taken new data to IDWeek 2026, and has an EU application under EMA assessment. What no company has published is what that means for demand. VacZine Analytics has built it: a granular North American demand model, complete as of October 2026, with a European analysis in preparation.
From VacZine Analytics MarketVIEW: Lyme Borreliosis Vaccines (VAMV024). Analysis current October 2026.
primary analysis after dose 4
in North America and Europe
14 August 2026
complete October 2026
Twenty-four years after withdrawal, a vaccine is at the regulator's door
LYMErix left the market in 2002 and no Lyme vaccine has been licensed since. VALOR changed that picture: a global, placebo-controlled Phase 3 that showed clear efficacy, narrowly missed its formal statistical bar on the confidence interval, and was nonetheless taken into regulatory review in Europe. The United States filing is guided for the second half of 2026.
IDWeek 2026: the data support the filing - and point to the booster question
The Phase 3 results were presented in Washington, DC this week. Three signals matter commercially: efficacy that is real and measurable, a tolerability profile that does not get in the way of a broad age range, and a protection pattern that rewards completing the course - and fades without further doses. That last point is a demand driver, not a footnote.
A ground-up North American demand model - complete, and not easy to rebuild
Lyme risk is intensely local, and so is demand for a Lyme vaccine. We have therefore built a purpose-designed model for the United States and Canada rather than one generic forecast. It forecasts doses and net revenue from launch to 2045 for ages 5 and over, and it is built to be interrogated: every input is sourced or stated as an assumption, with sensitivity testing across the key drivers.
The United States is modelled; Europe is next, and you can help shape it
The same vaccine meets very different markets. The North American analysis is ready now. A separate European analysis is being scoped, and its country coverage, depth and timing will be set with clients - so early conversations directly influence what is built.
Questions the report lets you answer before the market does
The North American model is ready now
This insight shows the shape and depth of the analysis; the figures and scenario outcomes are reserved for clients. Book a briefing to walk through the scenarios, or register your interest in the European analysis to help shape its scope.
View the report page Request a briefing Register interest in Europe